Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "2026年1月5日至2026年1月7日300750股价走势分析"

Looking for quality documents?
external link icon
CORRECTION -- Repligen to Report Third Quarter 2015 Financial Results
WALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report third quarter 2015 financial results on Thursday, November 5, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended September 30, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 63731917. In addition, a webcast will be accessible via the Investor Relations  section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 63731917. About Repligen
external link icon
Repligen to Report Third Quarter 2015 Financial Results
WALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report third quarter 2015 financial results on Thursday, November 5, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended September 30, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 63731917. In addition, a webcast will be accessible via the Investor Relations  section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 63731917. About Repligen
external link icon
Repligen to Present at Stephens Inc. Fall Investment Conference
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. An audio-only webcast of Dr. Herlihy's remarks and discussion with the audience will be accessible at the time of the presentation through the Investor Events section of Company's website. A replay of this webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen Completes Expansion of U.S. Facility
WALTHAM, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"), the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen's biopharmaceutical customers. "This expansion satisfies our goal to rapidly transfer ATF System operations, which we acquired from Refine Technology of
external link icon
Repligen Announces Share Repurchase Program
external link icon
Repligen Reports First Quarter 2015 Financial Results
- Product Sales Increase 45% to a Record $20.8 Million -

- Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the first quarter ended March 31, 2015. Below are the Company’s performance highlights for the quarter, followed by updated financial guidance for the year 2015 and access information for today’s webcast and conference call. First Quarter Financial Highlights   Bioprocessing product revenue for the first quarter of 2015 was $20.8 million, compared to $14.3 million for the first quarter of 2014, an increase of 45% including a negative impact of 12% from foreign currency translation. Total revenue for the first quarter of 2015 was comprised entirely of bioprocessing product revenue, while during the first quarter of 2014, total revenue of $16.3 million included a one-time upfront payment of $2.0 million from BioMarin Pharmaceutical Inc. under
external link icon
Repligen to Report First Quarter 2015 Financial Results
WALTHAM, Mass., April 29, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2015 financial results on Thursday, May 7, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting period ended March 31, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers or (404) 537-3372 for international callers. Dial-in participants must provide the passcode 34417361. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 34417361. About Repligen Corporation Repligen
external link icon
Repligen Reports Third Quarter 2013 Financial Results
- Product Revenue Grows 10% for the Quarter - - Net Income Grows 226% to $5.9 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EST - WALTHAM, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the third quarter ended September 30, 2013. Below are the Company's financial and business highlights for the third quarter, financial guidance for the year and dial-in numbers for today's conference call. Third Quarter 2013 Financial Highlights Bioprocessing product revenue for the third quarter of 2013 was $12.2 million, an increase of approximately10% over the third quarter of 2012.
  Total revenue for the third quarter of 2013 was $18.8 million, an increase of approximately 25% over the third quarter of 2012.
  Bioprocessing product gross profit margin was 53.5% for the third quarter of 2013, compared to 42.3% during the third quarter of 2012.
  Net income increased to $5.9 million
external link icon
Repligen to Report Third Quarter 2013 Financial Results
WALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2013 financial results on Thursday, November 7, 2013. The Company will issue a press release before the market opens, and will host a conference call at 9:00 a.m. EST to discuss business updates and financial results for the reporting period ended September 30, 2013. Repligen's third quarter conference call will be accessible by dialing (877) 415-3180 for domestic callers or (857) 244-7323 for international callers. Dial-in participants must provide the passcode 31006698. Alternatively, an audio webcast will be accessible via the Investor section of Repligen's website www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Replay listeners must provide the passcode 30270739.
external link icon
Repligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 2013
- Bioprocessing Revenue Increases to $42 Million, Total Revenue Reaches $63 Million in 2012 - - Year-over-Year Net Income Increases by $18 Million - WALTHAM, Mass., March 7, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for its fourth quarter and year ended December 31, 2012. The Company reported total revenue for the three-month period ended December 31, 2012 of $18,814,000, an increase of $11,649,000 as compared to total revenue of $7,165,000 for the same period in 2011. Revenue growth for the fourth quarter of 2012 was led by the Company's bioprocessing business which expanded as a result of its acquisition of Repligen Sweden AB in December 2011. Bioprocessing revenue was $9,709,000 for the three-month period ended December 31, 2012, more than three times the $3,115,000 of bioprocessing revenue generated during the same period in 2011. Royalty and other revenue for the three-month period ended December 31, 2012, which includes royalty